Shire OKs Generic Version of Blockbuster Drug

Law360, New York (January 20, 2006, 12:00 AM EST) -- Shire Pharmaceuticals Group PLC has penned a settlement deal with generic challenger Impax over a blockbuster drug for hyperactivity.

The deal allows Impax, a California pharmaceutical company, to market a generic version of Adderall in the United States until Jan. 1, 2010 for a royalty fee from the sales. After that date, the U.K. drug maker plans to launch an alternative treatment for attention deficit disorder, which it hopes will make up for any loss of profits from Adderall.

The deal salvages sales of the top-selling...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.